AU2018205730B2 - Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs - Google Patents

Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs Download PDF

Info

Publication number
AU2018205730B2
AU2018205730B2 AU2018205730A AU2018205730A AU2018205730B2 AU 2018205730 B2 AU2018205730 B2 AU 2018205730B2 AU 2018205730 A AU2018205730 A AU 2018205730A AU 2018205730 A AU2018205730 A AU 2018205730A AU 2018205730 B2 AU2018205730 B2 AU 2018205730B2
Authority
AU
Australia
Prior art keywords
ser
gly
netrin
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018205730A
Other languages
English (en)
Other versions
AU2018205730A1 (en
Inventor
Benjamin DUCAROUGE
Benjamin GIBERT
David GOLDSCHNEIDER
Patrick Mehlen
Anna Maria Rita REDAVID
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Centre Léon Bérard
Netris Pharma SAS
Université Claude Bernard Lyon 1
Original Assignee
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Centre Léon Bérard
Netris Pharma SAS
Université Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Centre Léon Bérard, Netris Pharma SAS, Université Claude Bernard Lyon 1 filed Critical Centre National de la Recherche Scientifique
Publication of AU2018205730A1 publication Critical patent/AU2018205730A1/en
Application granted granted Critical
Publication of AU2018205730B2 publication Critical patent/AU2018205730B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018205730A 2017-01-05 2018-01-05 Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs Active AU2018205730B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305014 2017-01-05
EP17305014.7 2017-01-05
PCT/EP2018/050289 WO2018127570A1 (en) 2017-01-05 2018-01-05 Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Publications (2)

Publication Number Publication Date
AU2018205730A1 AU2018205730A1 (en) 2019-07-11
AU2018205730B2 true AU2018205730B2 (en) 2024-05-30

Family

ID=57838304

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018205730A Active AU2018205730B2 (en) 2017-01-05 2018-01-05 Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Country Status (10)

Country Link
US (2) US12162932B2 (cg-RX-API-DMAC7.html)
EP (1) EP3565837B1 (cg-RX-API-DMAC7.html)
JP (2) JP7211952B2 (cg-RX-API-DMAC7.html)
KR (1) KR102679324B1 (cg-RX-API-DMAC7.html)
CN (1) CN110291105B (cg-RX-API-DMAC7.html)
AU (1) AU2018205730B2 (cg-RX-API-DMAC7.html)
CA (1) CA3048347A1 (cg-RX-API-DMAC7.html)
EA (1) EA039433B1 (cg-RX-API-DMAC7.html)
IL (1) IL267775B1 (cg-RX-API-DMAC7.html)
WO (1) WO2018127570A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
MX2024001308A (es) * 2021-07-27 2024-05-23 Netris Pharma Deteccion de netrina-1, prueba complementaria y terapia basada en radiaciones.
CA3246346A1 (en) * 2022-03-29 2023-10-05 Netris Pharma NEW MCL-1 INHIBITOR AND COMBINATION OF MCL-1 AND A BH3 MIMETIC, SUCH AS A BCL-2 INHIBITOR
WO2024095723A1 (ja) 2022-11-02 2024-05-10 シチズン・システムズ株式会社 プリンタ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104360A1 (en) * 2014-01-10 2015-07-16 Netris Pharma Novel anti-netrin-1 antibody

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2601352T3 (es) 2006-02-28 2017-02-14 Centre National De La Recherche Scientifique (Cnrs) Cribado para compuestos anti-cáncer usando actividad de netrina-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2609430A1 (en) 2010-08-26 2013-07-03 F.Hoffmann-La Roche Ag Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
UA122479C2 (uk) * 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CN104083762A (zh) * 2014-06-27 2014-10-08 中国科学院生物物理研究所 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途
NZ738406A (en) 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104360A1 (en) * 2014-01-10 2015-07-16 Netris Pharma Novel anti-netrin-1 antibody

Also Published As

Publication number Publication date
KR20190101991A (ko) 2019-09-02
EP3565837C0 (en) 2024-04-10
EP3565837B1 (en) 2024-04-10
CA3048347A1 (en) 2018-07-12
JP2022176250A (ja) 2022-11-25
EA201991302A1 (ru) 2019-11-29
WO2018127570A1 (en) 2018-07-12
IL267775B1 (en) 2026-06-01
IL267775A (en) 2019-09-26
EP3565837A1 (en) 2019-11-13
US20190315852A1 (en) 2019-10-17
AU2018205730A1 (en) 2019-07-11
JP2020503359A (ja) 2020-01-30
US12162932B2 (en) 2024-12-10
CN110291105A (zh) 2019-09-27
EA039433B1 (ru) 2022-01-27
CN110291105B (zh) 2024-03-01
KR102679324B1 (ko) 2024-06-28
US20250002572A1 (en) 2025-01-02
JP7211952B2 (ja) 2023-01-24

Similar Documents

Publication Publication Date Title
US20210115123A1 (en) Trispecific inhibitors for cancer treatment
CN112513080B (zh) Vista抗原结合分子
US20250002572A1 (en) Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
JP2022089856A (ja) Lag-3結合要素
US10407501B2 (en) Humanized or chimeric CD3 antibodies
JP2021508676A (ja) 抗tigit抗体並びに治療剤及び診断剤としてのその使用
CN111094346A (zh) 用于肿瘤特异性细胞消耗的化合物和方法
JP2020511481A (ja) 固形及び血液癌の治療のための併用療法
IL269577A (en) Bispecific anti-PD-L1-anti-TIM-3 antibodies
KR20220103708A (ko) 항-pd1 또는 항-pdl1 항체와의 병용물 형태로 항-ox40 항체를 사용하는 암 치료의 방법
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
EP3565593A1 (en) Compounds binding human cd160 and uses thereof
US20240190961A1 (en) Combination of anti-garp antibody and immunomodulator
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
KR20250160510A (ko) 항-lag3 항체, 약학적 조성물 및 용도
KR20250025384A (ko) Ceacam5 및 cd47에 대한 이중특이적 항체 및 ceacam5 및 cd3에 대한 이중특이적 항체의 조합 요법
EP4185388A1 (en) A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
HK40018012A (en) Compounds and methods for tumour-specific cell depletion

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)